<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) comprise a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of disorders characterized by ineffective hematopoiesis, with an increased propensity to develop <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The molecular basis for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progression is unknown, but a key element in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> disease progression is loss of chromosomal material (genomic instability) </plain></SENT>
<SENT sid="2" pm="."><plain>Using our two-step mouse model for myeloid leukemic disease progression involving overexpression of human mutant NRAS and BCL2 genes, we show that there is a stepwise increase in the frequency of DNA damage leading to an increased frequency of error-prone repair of double-strand breaks (DSB) by nonhomologous end-joining </plain></SENT>
<SENT sid="3" pm="."><plain>There is a concomitant increase in reactive oxygen species (ROS) in these transgenic mice with disease progression </plain></SENT>
<SENT sid="4" pm="."><plain>Importantly, RAC1, an essential component of the ROS-producing <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase, is downstream of <z:mp ids='MP_0011356'>RAS</z:mp>, and we show that ROS production in NRAS/BCL2 mice is in part dependent on RAC1 activity </plain></SENT>
<SENT sid="5" pm="."><plain>DNA damage and error-prone repair can be decreased or reversed in vivo by N-<z:chebi fb="9" ids="46887">acetyl</z:chebi> cysteine <z:chebi fb="11" ids="22586">antioxidant</z:chebi> treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Our data link gene abnormalities to constitutive DNA damage and increased DSB repair errors in vivo and provide a mechanism for an increase in the error rate of DNA repair with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> disease progression </plain></SENT>
<SENT sid="7" pm="."><plain>These data suggest treatment strategies that target <z:mp ids='MP_0011356'>RAS</z:mp>/RAC pathways and ROS production in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>